GLUE Graph | Monte Rosa Therapeutics, Inc.

GLUE Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue including tax $8.97M; Research and development $47.96M; Operating expenses $58.10M; Income tax $208.00K.
2026-03-31: Revenue including tax $4.21M; Research and development $44.07M; Operating expenses $54.24M; Income tax $52.00K.
2025-12-31: Revenue including tax $2.78M*; Research and development $41.98M*; Operating expenses $52.50M*; Income tax $59.00K*.
2025-09-30: Revenue including tax $12.77M; Research and development $36.68M; Operating expenses $45.74M; Income tax -$3.18M.

Agreement

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue including tax	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$8.97M	$47.96M	$58.10M	$208.00K	-$43.40M
2026-03-31	$4.21M	$44.07M	$54.24M	$52.00K	-$44.50M
2025-12-31	$2.78M*	$41.98M*	$52.50M*	$59.00K*	(m)
2025-09-30	$12.77M	$36.68M	$45.74M	-$3.18M	-$27.08M
2025-06-30	$23.19M	$30.65M	$38.75M	$1.20M	-$12.29M
2025-03-31	$84.93M	$32.19M	$40.89M	$822.00K	$46.88M
2024-09-30	$9.22M	$27.62M	$35.74M	$71.00K	-$23.86M
2024-06-30	$4.70M	$28.05M	$37.34M	$252.00K	-$30.31M
2024-03-31	$1.06M	$27.03M	$36.01M	$83.00K	-$31.97M
2023-09-30	$0.00	$28.31M	$36.97M	$170.00K	-$34.88M
2023-06-30	$0.00	$29.08M	$37.22M	$190.00K	-$35.18M
2023-03-31	$0.00	$26.75M	$34.26M	$0.00	-$32.04M
2022-09-30	(m)	$21.34M	$28.36M	$0.00	-$27.32M
2022-06-30	(m)	$20.94M	$27.23M	$0.00	-$26.47M
2022-03-31	(m)	$17.91M	$24.30M	$0.00	-$23.93M
2021-09-30	(m)	$15.12M	$19.87M	(m)	-$19.84M
2021-06-30	(m)	$14.64M	$18.12M	(m)	-$18.41M
2021-03-31	(m)	$9.27M	$11.50M	$0.00	-$12.28M
2020-09-30	(m)	$5.47M	$6.39M	(m)	-$6.56M
2020-06-30	(m)	$4.86M	$5.40M	(m)	-$5.36M
2020-03-31	(m)	(m)	(m)	(m)	-$4.30M

Revenue and expense 6 month

Period end	Revenue including tax	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$13.18M	$92.03M	$112.34M	$260.00K	-$87.90M
2025-06-30	$108.12M	$62.84M	$79.64M	$2.02M	$34.59M
2024-06-30	$5.76M	$55.08M	$73.35M	$335.00K	-$62.28M
2023-06-30	$0.00	$55.83M	$71.48M	$190.00K	-$67.22M
2022-06-30	(m)	$38.85M	$51.53M	$0.00	-$50.40M
2021-06-30	(m)	$23.91M	$29.63M	$0.00	-$30.68M
2020-06-30	(m)	$8.67M	$9.69M	$0.00	-$9.67M

Revenue and expense 9 month

Period end	Revenue including tax	Research and development	Operating expenses	Income tax	Net income
2025-09-30	$120.89M	$99.52M	$125.38M	-$1.16M	$7.51M
2024-09-30	$14.97M	$82.70M	$109.09M	$406.00K	-$86.14M
2023-09-30	$0.00	$84.14M	$108.45M	$360.00K	-$102.10M
2022-09-30	(m)	$60.19M	$79.89M	$0.00	-$77.72M
2021-09-30	(m)	$39.02M	$49.49M	$0.00	-$50.52M
2020-09-30	(m)	$14.14M	$16.07M	$0.00	-$16.22M

Revenue and expense 12 month

Period end	Revenue including tax	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$123.67M	$141.50M	$177.88M	-$1.10M	-$38.60M
2024-12-31	$75.62M	$121.56M	$156.73M	$2.57M	-$72.70M
2023-12-31	$0.00	$111.27M	$143.31M	$338.00K	-$135.35M
2022-12-31	(m)	$85.06M	$112.38M	$0.00	-$108.50M
2021-12-31	(m)	$57.16M	$72.88M	(m)	-$73.96M
2020-12-31	(m)	$24.00M	$28.01M	(m)	-$35.88M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Cullinan Therapeutics, Inc. (CGEM)	United States	$0.993B	-5.72
Odyssey Therapeutics, Inc. (ODTX)	United States	$0.960B
MeiraGTx Holdings plc (MGTX)	United States	$1.061B	16.10
Vor Biopharma Inc. (VOR)	United States	$1.091B	1.60
Sana Biotechnology, Inc. (SANA)	United States	$0.886B	-4.92
Candel Therapeutics, Inc. (CADL)	United States	$0.885B	-8.86
Attovia Therapeutics, Inc. (ATTO)	United States	$0.828B
Replimune Group, Inc. (REPL)	United States	$1.186B	-3.13
Solid Biosciences Inc. (SLDB)	United States	$0.802B	-5.07
4D Molecular Therapeutics, Inc. (FDMT)	United States	$0.733B	-4.10